8-KOther Events

REGENERON PHARMACEUTICALS, INC. 8-K Report (Apr 28, 2004)

Filed April 28, 2004For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on April 28, 2004, reporting an event that occurred on April 27, 2004. The filing is brief, indicating "Other Events and Required FD Disclosure" as the sole item. Without further details within this specific 8-K excerpt, it's challenging to provide in-depth operational or financial insights. However, for investors, the significance of this filing lies in its timing and the company's adherence to disclosure requirements. Any "Other Events" or "Required FD Disclosures" in SEC filings can potentially impact a company's stock price and investor confidence. Investors should refer to the full, unredacted filing to understand the specific event that triggered this report and its implications for Regeneron's business strategy, pipeline, or regulatory status.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report on Form 8-K.
  • 2The report was filed on April 28, 2004, with the earliest event date being April 27, 2004.
  • 3The filing falls under Item 5: Other Events and Required FD Disclosure.
  • 4The provided excerpt does not contain specific details about the nature of the event.
  • 5The filing indicates the company's principal executive offices are located in Tarrytown, NY.
  • 6Regeneron's Commission File Number is 0-19034.

Frequently Asked Questions

The provided excerpt of the 8-K filing for Regeneron Pharmaceuticals, Inc. does not detail the specific event. It only indicates that the filing pertains to 'Other Events and Required FD Disclosure' and occurred on April 27, 2004.

An 8-K filing is crucial for investors as it reports significant events that could affect a company's financial health or stock value. These events can include changes in corporate leadership, material agreements, bankruptcy, or other major business developments that are not covered by regular periodic reports.

To understand the specific event and its implications, investors should access the full, unredacted Form 8-K filing for Regeneron Pharmaceuticals, Inc. filed on April 28, 2004, through the SEC's EDGAR database or the company's investor relations website.